These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12707858)

  • 1. Recent advances in Japanese encephalitis.
    Solomon T
    J Neurovirol; 2003 Apr; 9(2):274-83. PubMed ID: 12707858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japanese encephalitis vaccines: current vaccines and future prospects.
    Monath TP
    Curr Top Microbiol Immunol; 2002; 267():105-38. PubMed ID: 12082985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Appaiahgari MB; Vrati S
    Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
    Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
    J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese encephalitis vaccines: moving away from the mouse brain.
    Zanin MP; Webster DE; Martin JL; Wesselingh SL
    Expert Rev Vaccines; 2003 Jun; 2(3):407-16. PubMed ID: 12903806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The progress and challenge of Japanese encephalitis control and prevention in China].
    Wang HY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Feb; 53(2):133-135. PubMed ID: 30744284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Fischer M; Lindsey N; Staples JE; Hills S;
    MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV).
    Appaiahgari MB; Vrati S
    Expert Opin Biol Ther; 2012 Sep; 12(9):1251-63. PubMed ID: 22775524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese encephalitis: development of new candidate vaccines.
    Bharati K; Vrati S
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):313-24. PubMed ID: 16597211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new vaccines against dengue fever and Japanese encephalitis.
    Kinney RM; Huang CY
    Intervirology; 2001; 44(2-3):176-97. PubMed ID: 11509879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric classical swine fever (CSF)-Japanese encephalitis (JE) viral replicon as a non-transmissible vaccine candidate against CSF and JE infections.
    Yang Z; Wu R; Li RW; Li L; Xiong Z; Zhao H; Guo D; Pan Z
    Virus Res; 2012 Apr; 165(1):61-70. PubMed ID: 22285514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.
    Yu Y
    Vaccine; 2010 May; 28(21):3635-41. PubMed ID: 20226891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product review on the JE vaccine IXIARO.
    Firbas C; Jilma B
    Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B; Jia L; Xu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric live attenuated vaccine against Japanese encephalitis.
    Jones T
    Expert Rev Vaccines; 2004 Jun; 3(3):243-8. PubMed ID: 15176941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a recombinant vaccine against Japanese encephalitis.
    Kaur R; Vrati S
    J Neurovirol; 2003 Aug; 9(4):421-31. PubMed ID: 12907387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies in the development of Japanese encephalitis vaccine: expression of virus envelope glycoprotein V3 (E) gene in yeast.
    Fujita H; Sumiyoshi H; Mori C; Manabe S; Takagi M; Yoshida I; Morita K; Fuke I; Fukai K; Igarashi A
    Bull World Health Organ; 1987; 65(3):303-8. PubMed ID: 2822272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.